SynthesisPloS one2015
Enhancer of zeste homolog 2 as an independent prognostic marker for cancer: a meta-analysis.
Synthesis in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 3 syntheses or guidelines pooled it, 19 citations in OpenAlex.
- The role of EZH2 in overall survival of colorectal cancer: a meta-analysis.Scientific reports · 2017Pooled it
- Pooled it
- Prognostic value of high EZH2 expression in patients with different types of cancer: a systematic review with meta-analysis.Oncotarget · 2016Pooled it
- The role of histone methylation in renal cell cancer: an update.Molecular biology reports · 2023Review
- Article
- EZH2-inhibitor DZNep enhances apoptosis of renal tubular epithelial cells in presence and absence of cisplatin.Cell division · 2020Article
- Increased expression of EZH2 indicates aggressive potential of urothelial carcinoma of the bladder in a Chinese population.Scientific reports · 2018Article
- MUC1-C activates polycomb repressive complexes and downregulates tumor suppressor genes in human cancer cells.Oncogene · 2018Review
- Association of clinicopathologic characteristics and outcomes withOncoTargets and therapy · 2018Article
- MUC1-C activates EZH2 expression and function in human cancer cells.Scientific reports · 2017Article
- Epigenetic determinants of metastasis.Molecular oncology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNovel biomarkers are of particular interest for predicting cancer prognosis. This study aimed to explore the associations between enhancer of zeste homolog 2 (EZH2) and patient survival in various cancers.
methodsRelevant literature was retrieved from PubMed and Web of Science databases. Pooled hazard ratios (HRs), odds ratios (ORs), and 95% confidence intervals (CIs) were calculated.
resultsForty-nine studies (8,050 patients) were included. High EZH2 expression was significantly associated with shorter overall (hazard ratio [HR] 1.74, 95% CI: 1.46-2.07), disease-free (HR 1.59, 95% CI: 1.27-1.99), metastasis-free (HR 2.19, 95% CI: 1.38-3.47), progression-free (HR 2.53, 95% CI: 1.52-4.21), cancer-specific (HR 3.13, 95% CI: 1.70-5.74), and disease-specific (HR 2.29, 95% CI: 1.56-3.35) survival, but not recurrence-free survival (HR 1.38, 95% CI: 0.93-2.06). Moreover, EZH2 expression significantly correlated with distant metastasis (OR 3.25, 95% CI: 1.07-9.87) in esophageal carcinoma; differentiation (OR 3.00, 95% CI: 1.37-6.55) in non-small cell lung cancer; TNM stage (OR 3.18, 95% CI: 2.49-4.08) in renal cell carcinoma; and histological grade (OR 4.50, 95% CI: 3.33-6.09), estrogen receptor status (OR 0.15, 95% CI: 0.11-0.20) and progesterone receptor status (OR 0.30, 95% CI: 0.23-0.39) in breast cancer.
conclusionsOur results suggested that EZH2 might be an independent prognostic factor for multiple survival measures in different cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.